Skip to main content

Table 20 Binding or neutralizing antibodies directed against anti-CGRP monoclonal antibodies in available randomized clinical trials

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Author, Year Phase, setting Participants (n) Follow-up Binding antibodies Neutalizing antibodies Clinical implications
Eptinezumab
 Dodick, 2014 [32] II, EM 174 3 months 11/81 None
Erenumab
 Sun, 2016 [44] II, EM 483 3 months 8/104 for 70 mg 1/104 for 70 mg None
 Tepper, 2017 [45] II, CM 667 3 months 11/190 for 70 mg
3/188 for 140 mg
0 None
 STRIVE [36] III, EM 955 6 months 8.0% for 70 mg
3.2% for 140 mg
0.2% for 70 mg
0 for 140 mg
None
 ARISE [35] III, EM 577 3 months 4.3% for 70 mg 0.4% for 70 mg* None
Fremanezumab
 Bigal, 2015 [27] IIb, EM 297 3 months 1%§ None
 Bigal, 2015 [26] IIb, CM 264 3 months 1%§ None
 HALO EM [34] III, EM 875 3 months 1.4% for the monthly dosing
0 for single high dose
None
 HALO CM [41] III, CM 1130 3 months 1% None
Galcanezumab
 REGAIN [31] III, CM 836 3 months 2.7% for 120 mg 2.6% for 240 mg 2.3% for 120 mg 1.5% for 240 mg None
 Dodick, 2014 [33] II, EM 218 3 months 15.7%#   None
 Skljarevski, 2018 [42] IIb, EM 936 3 months None
 EVOLVE 1 [43] III, EM 1671 6 months 3.5% for 120 mg¶
5.2% for 240 mg¶
0.2% None
 EVOLVE 2 [51] III, EM 922 6 months 8.6% for 120 mg¶5.1% for 240 mg¶ 3.1% None
  1. * positive at week 4 for but negative at each subsequent visit; §patients were positive at baseline; #including 6.2% of patients who were positive at baseline; ¶only treatment emergent antibodies. The EVOLVE 2 study line under Galcanezumab was replaced with Skljarevski and a new line was added for EVOLVE 2, linked to reference 51